HAVCR2 and lymphoma: Tim-3+ ECs modulated T cell response to lymphoma surrogate antigens by suppressing activation of CD4+ T lymphocytes through the activation of the interleukin-6–STAT3 pathway, inhibiting Th1 polarization, providing protective immunity, and facilitating the establishment of lymphoma immune tolerance.